You are here

  • Home
  • Archive
  • Volume 10, Issue 11
  • Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

Article info

Article menu
Clinical/translational cancer immunotherapy
Original research
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia

Authors

  • Matthew G Cyr Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USASkaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Maissa Mhibik Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Junpeng Qi Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Haiyong Peng Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Jing Chang Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Erika M Gaglione Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • David Eik Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • John Herrick Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Thomas Venables Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Scott J Novick Department of Molecular Medicine, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Valentine V Courouble Skaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USADepartment of Molecular Medicine, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Patrick R Griffin Department of Molecular Medicine, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  • Adrian Wiestner Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA PubMed articlesGoogle scholar articles
  • Christoph Rader Department of Immunology and Microbiology, UF Scripps Biomedical Research, University of Florida, Jupiter, Florida, USASkaggs Graduate School of Chemical and Biological Sciences, The Scripps Research Institute, Jupiter, Florida, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Christoph Rader; crader{at}scripps.edu
View Full Text

Citation

Cyr MG, Mhibik M, Qi J, et al
Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
Journal for ImmunoTherapy of Cancer 2022;10:e004850. doi: 10.1136/jitc-2022-004850

Publication history

  • Accepted October 25, 2022
  • First published November 28, 2022.
Online issue publication 
October 18, 2023

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.